Oliver Bandmann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8688507/publications.pdf

Version: 2024-02-01

82 papers	5,477 citations	101535 36 h-index	85537 71 g-index
83 all docs	83 docs citations	83 times ranked	7642 citing authors

#	Article	IF	Citations
1	Wilson's disease and other neurological copper disorders. Lancet Neurology, The, 2015, 14, 103-113.	10.2	751
2	Mitochondrial function and morphology are impaired in parkinâ€mutant fibroblasts. Annals of Neurology, 2008, 64, 555-565.	5.3	339
3	Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nature Neuroscience, 2009, 12, 1129-1135.	14.8	288
4	A genetic study of Wilsonâ€™s disease in the United Kingdom. Brain, 2013, 136, 1476-1487.	7.6	288
5	Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology, 2010, 75, 2017-2020.	1.1	257
6	The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinsonâ€™s Disease. Cell Reports, 2018, 23, 2976-2988.	6.4	239
7	p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. Journal of Neurochemistry, 2007, 100, 070209222715077-???.	3.9	177
8	Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio). Brain, 2009, 132, 1613-1623.	7.6	173
9	Neuronal dark matter: the emerging role of microRNAs in neurodegeneration. Frontiers in Cellular Neuroscience, 2013, 7, 178.	3.7	167
10	Parkinson's disease: insights from pathways. Human Molecular Genetics, 2010, 19, R21-R27.	2.9	151
11	Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder. Sleep, 2017, 40, .	1.1	138
12	Progress towards therapies for disease modification in Parkinson's disease. Lancet Neurology, The, 2021, 20, 559-572.	10.2	136
13	Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. Neurology, 2013, 80, 1740-1745.	1.1	124
14	Zebrafish as a new animal model for movement disorders. Journal of Neurochemistry, 2008, 106, 1991-1997.	3.9	121
15	Glucocerebrosidase 1 deficientDanio reriomirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death. Human Molecular Genetics, 2015, 24, 6640-6652.	2.9	108
16	Genetic zebrafish models of neurodegenerative diseases. Neurobiology of Disease, 2010, 40, 58-65.	4.4	107
17	UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2 ^{G2019S} carriers and in vivo. Neurology, 2015, 85, 846-852.	1.1	105
18	The Prevalence of Juvenile Huntington's Disease: A Review of the Literature and Meta-Analysis. PLOS Currents, 2012, 4, e4f8606b742ef3.	1.4	105

#	Article	IF	Citations
19	Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinsonâ€™s disease. Brain, 2013, 136, 3038-3050.	7.6	102
20	Evaluation of the Unified Wilson's Disease Rating Scale (UWDRS) in German patients with treated Wilson's disease. Movement Disorders, 2008, 23, 54-62.	3.9	94
21	pH-Sensitive Tubular Polymersomes: Formation and Applications in Cellular Delivery. ACS Nano, 2014, 8, 4650-4661.	14.6	91
22	Inhibition of the mitochondrial calcium uniporter rescues dopaminergic neurons in pink1^{â^'/â^'} zebrafish. European Journal of Neuroscience, 2017, 45, 528-535.	2.6	74
23	Neurodegenerative disorders: Parkinson's disease and Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1058-1063.	1.9	72
24	Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease. Molecular and Cellular Probes, 1994, 8, 519-525.	2.1	69
25	TigarB causes mitochondrial dysfunction and neuronal loss in PINK1 deficiency. Annals of Neurology, 2013, 74, 837-847.	5.3	68
26	Ursodeoxycholic Acid Improves Mitochondrial Function and Redistributes Drp1 in Fibroblasts from Patients with Either Sporadic or Familial Alzheimer's Disease. Journal of Molecular Biology, 2018, 430, 3942-3953.	4.2	63
27	Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients. Movement Disorders, 2004, 19, 192-196.	3.9	62
28	C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis. Brain, 2019, 142, 3771-3790.	7.6	59
29	C9ORF72 expansions, parkinsonism, and Parkinson disease. Neurology, 2013, 81, 808-811.	1.1	57
30	Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting â€œsleep attacksâ€• Movement Disorders, 2004, 19, 1279-1284.	3.9	51
31	Parkinsonâ€™s Disease in Sub-Saharan Africa: A Review of Epidemiology, Genetics and Access to Care. Journal of Movement Disorders, 2018, 11, 53-64.	1.3	45
32	Restriction of mitochondrial calcium overload by mcu inactivation renders neuroprotective effect in Zebrafish models of Parkinson's disease. Biology Open, 2019, 8, .	1.2	45
33	Wilsonâ€™s disease: update on pathogenesis, biomarkers and treatments. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1053-1061.	1.9	44
34	Deep learning for automatic cell detection in wide-field microscopy zebrafish images. , 2015, , .		43
35	Epidemiology and introduction to the clinical presentation of Wilson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 142, 7-17.	1.8	39
36	Genetic aspects of Parkinson's disease. Movement Disorders, 1998, 13, 203-211.	3.9	38

#	Article	IF	Citations
37	Detailed genotyping demonstrates association between the slow acetylator genotype for N-Acetyltransferase 2 (NAT2) and familial parkinson's disease. Movement Disorders, 2000, 15, 30-35.	3.9	37
38	Prolonged generalized dystonia after chronic cerebellar application of kainic acid. Brain Research, 2012, 1464, 82-88.	2.2	36
39	Animal models of Wilson disease. Journal of Neurochemistry, 2018, 146, 356-373.	3.9	36
40	Porphyria: often discussed but too often missed. Practical Neurology, 2018, 18, 352-358.	1.1	36
41	Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinsonâ€™s disease. Progress in Neurobiology, 2020, 187, 101772.	5.7	35
42	Structural and Functional Neuroimaging of Visual Hallucinations in Lewy Body Disease: A Systematic Literature Review. Brain Sciences, 2017, 7, 84.	2.3	31
43	The GTP-cyclohydrolase I gene in atypical Parkinsonian patients: a clinico-genetic study. Journal of the Neurological Sciences, 1996, 141, 27-32.	0.6	23
44	Lack of association between the interleukin-1 alpha (â^'889) polymorphism and early-onset Parkinson's disease. Neuroscience Letters, 2004, 359, 195-197.	2.1	23
45	Serum FGF-21, GDF-15, and blood mtDNA copy number are not biomarkers of Parkinson disease. Neurology: Clinical Practice, 2020, 10, 40-46.	1.6	23
46	PINK1 deficiency impairs adult neurogenesis of dopaminergic neurons. Scientific Reports, 2021, 11, 6617.	3.3	21
47	Neuroanatomical and cognitive correlates of visual hallucinations in Parkinsonâ€™s disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis. Neuroscience and Biobehavioral Reviews, 2021, 128, 367-382.	6.1	21
48	Brain-derived neurotrophic factor: A genetic risk factor for obsessive-compulsive disorder and Tourette syndrome?. Movement Disorders, 2006, 21, 881-883.	3.9	19
49	Ablation of the pro-inflammatory master regulator miR-155 does not mitigate neuroinflammation or neurodegeneration in a vertebrate model of Gaucher's disease. Neurobiology of Disease, 2019, 127, 563-569.	4.4	19
50	Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinsonâ€™s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study. BMJ Open, 2020, 10, e038911.	1.9	18
51	Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver. The Lancet Gastroenterology and Hepatology, 2022, 7, 560-575.	8.1	18
52	The genetic and clinicoâ€pathological profile of earlyâ€onset progressive supranuclear palsy. Movement Disorders, 2019, 34, 1307-1314.	3.9	16
53	Neuroimaging correlates of brain injury in Wilsonâ€™s disease: a multimodal, whole-brain MRI study. Brain, 2022, 145, 263-275.	7.6	16
54	Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease. Movement Disorders, 2021, 36, 503-508.	3.9	15

#	Article	IF	Citations
55	HLA-DRB genotyping in Gilles de la Tourette patients and their parents. , 2003, 119B, 60-64.		13
56	The Influence of the Zebrafish Genetic Background on Parkinson's Diseaseâ€“Related Aspects. Zebrafish, 2011, 8, 103-108.	1.1	10
57	Translational approaches to restoring mitochondrial function in Parkinson's disease. FEBS Letters, 2018, 592, 776-792.	2.8	10
58	GCH1 Deficiency Activates Brain Innate Immune Response and Impairs Tyrosine Hydroxylase Homeostasis. Journal of Neuroscience, 2022, 42, 702-716.	3.6	10
59	Prevalence of the H1069Q mutation in ATP7B in discordant pairs with earlyâ€onset Parkinson's Disease. Movement Disorders, 2006, 21, 1789-1790.	3.9	9
60	Computer-aided diagnosis for (123I)FP-CIT imaging: impact on clinical reporting. EJNMMI Research, 2018, 8, 36.	2.5	9
61	Slow N -acetyltransferase 2 status leads to enhanced intrastriatal dopamine depletion in 6-hydroxydopamine-lesioned rats. Experimental Neurology, 2004, 187, 199-202.	4.1	8
62	Complicated autosomal recessive hereditary spastic paraplegia. Neurology, 2008, 70, 1375-1376.	1.1	8
63	Parkinson disease, cancer, and LRRK2: Causation or association?. Neurology, 2012, 78, 772-773.	1.1	8
64	Reduced habit-driven errors in Parkinsonâ€™s Disease. Scientific Reports, 2019, 9, 3423.	3.3	7
65	TIGAR inclusion pathology is specific for Lewy body diseases. Brain Research, 2019, 1706, 218-223.	2.2	7
66	Neuroimaging Correlates of Cognitive Deficits in Wilson's Disease. Movement Disorders, 0, , .	3.9	7
67	Delayed toxicâ€“hypoxic encephalopathy. Practical Neurology, 2013, 13, 114-119.	1.1	6
68	The common PARK8 mutation LRRK2 G2019S is not a risk factor for breast cancer in the absence of Parkinsonâ€™s disease. Journal of Neurology, 2013, 260, 2177-2178.	3.6	5
69	Cognitive correlates and baseline predictors of future development of visual hallucinations in dementia with Lewy bodies. Cortex, 2021, 142, 74-83.	2.4	5
70	Liver transplant for neurologic Wilson disease. Neurology, 2020, 94, 907-908.	1.1	5
71	Epsilon-sarcoglycan is not involved in sporadic Gilles de la Tourette syndrome. Neurogenetics, 2005, 6, 55-56.	1.4	3
72	Biomarkers for PD. Neurology, 2013, 80, 608-609.	1.1	3

#	Article	IF	Citations
73	The subresolution DaTSCAN phantom. Nuclear Medicine Communications, 2018, 39, 268-275.	1.1	3
74	Three-Dimensional Deconvolution of Wide Field Microscopy with Sparse Priors: Application to Zebrafish Imagery. , 2014, , .		2
75	Targeting mechanisms in cognitive training for neurodegenerative diseases. Neural Regeneration Research, 2021, 16, 500.	3.0	2
76	Heterozygous mutations in the FGF8, SHH and nodal/transforming growth factor beta pathways do not confer increased dopaminergic neuron vulnerabilityâ€"A zebrafish study. Neuroscience Letters, 2013, 532, 55-58.	2.1	1
77	The documentation of consent and disclosure of neurogenetic testing outside clinical genetics. Neurogenetics, 2014, 15, 19-21.	1.4	1
78	Mental disorders in movement disorders. Current Opinion in Psychiatry, 1998, 11, 315-319.	6.3	1
79	Genetics of multiple system atrophy. Neurology, 2016, 87, 1530-1531.	1.1	0
80	Huntington disease. Neurology, 2016, 87, 247-248.	1.1	0
81	Neurological letter from Bangladesh. Practical Neurology, 2020, 20, 435.2-445.	1.1	0
82	Plasma neurofilament light levels as a novel biomarker for neurological involve- ment in Wilsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A6.2-A6.	1.9	0